918²«ÌìÌÃ

½Ó´ý»á¼û918²«ÌìÌùٷ½ÍøÕ¾£¡

ÎÄÏ××ÊÁÏ

ÁªÏµ918²«ÌìÌÃ

918²«ÌìÌÃ

µç»°£º0570£­8788056

´«Õ棺0570£­8788381

ÓÊÏ䣺zjgykp@163.com

µØµã£ºÕã½­Ê¡áéÖÝÊж«¸Û¾­¼Ã¿ª·¢Çø

¶«¸Û4·2ºÅ

ÄúËùÔÚµÄÄ¿½ñλÖãºÊ×Ò³ > ÎÄÏ××ÊÁÏ > Ö×ÁöÀàÎÄÏ×
  • ¹û½ºÔÚ°©Ö¢ÖÎÁÆÖеÄÓ¦ÓÃ
  • Ðû²¼Ê±¼ä£º 2019/5/15¡¡µã»÷´ÎÊý£º5671¡¡
  •  

      ¹û½ºÔÚ°©Ö¢ÖÎÁÆÖеÄÓ¦ÓÃ

          ÕÅÎIJ©¡±£¬ÕÅêÏ£¬ÐìƼ2

          (I.ÐÂÏçҽѧԺÉúÃü¿Æѧ¼¼ÊõѧԺ£¬ºÓÄÏÐÂÏç453003;

          2.ÐÂÏçҽѧԺҩѧԺ£¬ºÓÄÏÐÂÏç453003)

          ÕªÒª:¹û½ºÊÇÖ²Îïϸ°û±ÚÖÐÖÖÒÔ¾Û°ëÈéÌÇÈ©ËáΪ¹Ç¼Ü¡¢¸»º¬ÖÐÐÔÌÇ·ÖÖ¦½á¹¹µÄÔÓ¶àÌÇ¡£×÷ΪÉÅÄÃÏËάµÄ¹û½ºÄÜÊdz£¼ûµÄÉÅʳÏËάÉí·Ö£¬ÄÜÒÖÖƽ᳦°©¡£¹û½º¾­¸ÄÐԿɽµ½âΪµÍ·Ö×ÓÁ¿¡¢µÍõ¥»¯¶È¡¢¿ÉÉúÎïÀûÓõÄƬ¶Î£¬ÖØÒªµÄÀý×ÓÊǸÄÐÔ¸ÌéÙ¹û½º(MCP). MCP ¿Éͨ¹ýÓë°ëÈéÌÇÄý¼¯ËØ-3Ï໥×÷ÓöøÒÖÖÆÖ×ÁöÉú³¤¡¢ÓÕµ¼Ï¸°ûµ÷Íö¡¢ÔöÇ¿Ö×Áöϸ°û¶Ô»¯ÁÆÒ©ÎïµÄÃô¸ÐÐÔ¡¢ÒÖÖÆÖ×ÁöѪ¹ÜÐÂÉú¡¢ÒÖÖÆתÒƺÍÔöÇ¿»úÌåÃâÒßÏìÓ¦¡£¹û½º¸»ÓÐôÈ»ù¡¢ôÇ»ùµÈ¹¦Ð§»ùÍÅ¡¢Ò×ÓÚÐÞÊΣ¬ÊÇÁ¼ºÃµÄ¿¹Ö×Áö¸øҩϵͳµÄÖÊÁÏ¡£±¾ÎÄÊ×ÏÈ×ܽáÁ˹û½ºµÄ½á¹¹Ìص㣬ȻºóÖصãÆÊÎöÁË¿ÉÉúÎïÀûÓùû½ºÆ¬¶ÎµÄ¿¹Ö×Áö»úÖÆ¡¢ÎüÊÕ»úÖƺͿ¹Ö×Áö¹¹Ð§¹ØϵµÈ£¬×îºóÕ¹ÍûÁ˽«¹û½º¿ª·¢Îª¹¦Ð§Ê³Æ·»ò¿¹Ö×ÁöÒ©Îï±£´æµÄÎÊÌâ¼°Ç°¾°¡£

          Òªº¦´Ê:¿¹Ö×Áö£¬°ëÈéÌÇÄý¼¯ËØ-3,¸ÄÐÔ¸ÌéÙ¹û½º£¬¹û½º£¬ÉúÎïÀûÓöÈ

          ÒýÑÔ

          ¹û½ºÊÇÒ»ÖÖ´ÓÖ²Îïϸ°û±Ú»ñµÃµÄÅÓ´ó¶àÌÇ¡£ÉÌÆ·»¯µÄ¹û½ºÔÚʳƷºÍÒ½Ò©¹¤ÒµÖпÉÓÃ×÷Îȶ¨¼Á¡¢Ôö³í¼Á¡¢È黯¼ÁºÍÄÍËὺÄý¼ÁµÈ£¬ÊÇÖÖÎÞ¶¾ÎÞº¦µÄÌìÈ» ʳƷÌí¼Ó¼ÁºÍÒ©Î︨¿Æ(Wicker, 2014)¡£Æ¾¾Ý·Ö×ÓÁ¿»ò¼Ó¹¤ÐÔÖÊÇø·Ö£¬¹û½º¿ÉÒÔ·ÖΪ½Ï¸ß·Ö×ÓÁ¿µÄÌìÈ»¹û½ººÍ½ÏµÍ·Ö×ÓÁ¿µÄ¸ÄÐÔ¹û½º¡£ÌìÈ»¹û½º³£×÷ΪÉÅʳÏËά(dietary fiber, DF)±£´æÓÚʳÎïÖС£DFÊÇÒ»À಻¿ÉÔÚÈË賦µÀÄÚÏû»¯¡¢µ«Äܱ»´ó³¦ÄÚ΢ÉúÎï½µ½âºÍÀûÓõĶàÌÇ»òµÍ¾ÛÌÇ£¬ËüÃǵķÖ×ÓÁ¿ÂþÑÜ¿ÉÔÚÉÏÍòÖÁÉÏ°ÙÍòÖ®¼ä¡£ÉÅʳÏËά¹û½º(ÏÂÎļò³ÆDF-Pec¶Ô¸ßѪѹ¡¢±ãÃصÈÂýÐÔ²¡Óж¨ÁÆЧ£¬²¢¾ßÓнµµÍѪÌÇ¡¢ÑªÖ¬¡¢¼õÉÙµ¨¹Ì´¼¡¢½â³ýǦÖж¾µÈ×÷ÓÃ(Zhang, 2006)¡£½üÄêÀ´£¬ÓÉÓÚ·¢Ã÷¸ÄÐÔ¸ÌéÙ¹û½º(modified citrus pectin, MCP)¾ßÓп¹Ö×ÁöתÒÆ»îÐÔ£¬Æä

    Ó¦ÓÃDZÁ¦ÒýÈËעĿ(Leclere, Cutsem, & Michiels, 2013; Zhang, 2006)¡£

          È«ÇòÿÄêÔ¼760ÍòÖ×ÁöËÀÍö²¡Àý( World Health Organization, 2008)¡£¾¡¹ÜÊÖÊõ¡¢»¯ÁƺͷÅÁƵȹŰåÊÖ¶ÎÒÔ¼°ÃâÒßÖÎÁÆ¡¢»ùÒòÖÎÁÆ¡¢½éÈëÖÎÁƵÈÐÂÊֶβ»¾ø¸ïУ¬¿ÉÊÇתÒÆ( metastasis )ÈÔÈ»ÊÇ»¼ÕßËÀÍöµÄÖ÷Òò(Zhang, 2006; Zhang et al, 2013)¡£×ªÒÆʹÊÖÊõÖÎÁÆʱ¼ä´°¿Úɥʧ£¬¶ø²»µÃ²»½ÓÄÉ·ÅÁƺͻ¯ÁƵȶԻúÌåÉ˺¦´óµÄ¼Æ»®¡£»¯ÁÆÒ©Îï½ÓÄÉϸ°û¶¾ÐÔ(cytotoxicity) Ä£ÐÍɸѡ£¬ÖÎÁÆÖ¸ÊýµÍ¡¢×¨Ò»ÐԲ²¢ÇÒÖ×Áöϸ°ûÄÍÒ©ÐÔÍùÍùµ¼Ö»¯ÁÆʧ°Ü(Leclereetal,2013)¡£¹û½ºÔÚÖ×ÁöÖÎÁÆÖеÄÓ¦ÓÃDZÁ¦£¬Ö÷ÒªÌåÏÖÔÚÒÔϼ¸¸ö·½Ãæ: DF-Pec ¶Ô½á³¦°©µÄÔ¤·ÀºÍÖÎÁÆ×÷ÓᢸÄÐÔ¹û½ºÆ¬¶ÎµÄ¿¹Ö×Áö»îÐÔ¡¢¹û½º×÷ΪÃâÒßÔöÇ¿¼Á¡¢¹û½º×÷ΪҩÎïÔØÌå¡£±¾×ÛÊöÖصã¶Ô¹û½ºÔÚ¿¹Ö׸»ÖÎÁÆÖеÄÓ¦Óü°×÷ÓûúÖƽøÐÐ×ܽá¡£

    1.¹û½º½á¹¹

          ¹û½ºµÄ½á¹¹-Ò»°ã·Ö ΪÈý´óÀà:ͬ¾Û°ëÈéÌÇÈ©Ëá(homogalaturonan, HG),ÊóÀîÌÇ°ëÈéÌÇÈ©Ëá¾ÛÌÇ-I ( rhannogalacturonan-I, RG-I)ºÍÈ¡´ú°ëÈéÌÇÈ©Ëá¾ÛÌÇ( substituted galacturonans, GS ) (Caffall & Mohnen, 2009; Leclere et al, 2013;Zhang, 2006; Zhang. Liu, & Gao, 2010)¡£¹û½º½á¹¹ËæÀ´Ô´¡¢¼Ó¹¤¹¤ÒÕµÈÒòËرä¸ï½Ï´ó£¬Í¨³£HGÕ¼Ô¼65%£¬RG-I Õ¼20-35%£¬ÆäËüΪGS,¸ÌéÙ¹û½º(citrus pectin,CP)ÖеÄRG-Iº¬Á¿Ô¶¸ßÓÚRG-Il(Mohnen,2008)¡£HGÊÇÓÉD-°ëÈéÌÇÈ©Ëá(D-galacturonic acid, GalpA)¾­a-1, 4ÌÇÜÕ¼üÁ¬½ÓµÄÖ±Á´·Ö×Ó¡£ÉÌÒµÀ´Ô´µÄCPÆäHG²¿·ÖµÄ³¤¶ÈԼĪΪ20 kD (Thibault et al,1993; Yapo, Lerouge, Thibault &Ralet, 2007)¡£Æ¾¾ÝGalpAµÄC-6λôÈ»ù¼×õ¥»¯Ë®Æ½(degree of methylation, DM)£¬¹û½ºÒà¿É·ÖΪ¸ßõ¥¹û½ººÍµÍõ¥¹û½º,ËüÃÇÔÚʳƷ¹¤ÒµÖеÄÓÃ;Óкܴó²î±ð¡£±ðµÄ£¬GalpAÆäC-2»òC-3λôÇ»ù¿É±»ÒÒõ¥»¯£¬²¢ÓÃDAÀ´ÌåÏÖõ¥»¯Ë®Æ½( degree ofacetylation, DAc)¡£RG-I º¬ÓÐÓÉÊóÀîÌǺͰëÈéÌÇÈ©Ëá×é³ÉµÄ½¹µãÖظ´Æ¬¶Î:[(¡ú4)-a-D-GalpA-(1¡ú2)-a-L-Rhap-(1-)]n. RGIµÄGalpA-°ã²»Á¬½Ó ÆäËüÖ§Á´¡£Ô¼20-80%ÊóÀîÌǵÄC4ôÇ»ùÁ¬½ÓÓжàÖֽṹ¸÷ÒìµÄÖ§Á´£¬Æ¾¾ÝÖ²ÎïÀ´Ô´µÄ²î±ðÖ÷Òª±£´æÈýÖÖÀàÐ͵ÄƬ¶Î:ÓÉ-(1,4)¼üÁ¬ ½ÓµÄ¹Ñ¾Û°ëÈéÌÇ£¬I ÐÍ°¢À­²®°ëÈé¾ÛÌÇ(type I arabinogalactan, AG-I)ºÍI1ÐÍ°¢À­²®°ëÈé¾ÛÌÇ(type II arabinogalactan, AG-I)µÈÈýÖÖÀàÐÍ.CPµÄRG-IÖ÷ÒªÓɹѾ۰ëÈéÌÇAG-I×é³É, AG-IÓÉB-(1,4)¼üºÍB-(1,3)¼üÁ¬½ÓµÄÁ½ÖÖÀàÐ͵İëÈé¹Ñ¾ÛÌÆ×é³É¡£L°¢À­²®ÌǾ­³£ÒÔ0(1,5)¼üÁ¬½Óµ½-(1,4)¼ü×é³ÉµÄ°ëÈé¹Ñ¾ÛÌǵÄÖмä»òÄ©¶Ë(Gao et al, 2012b; Hinz et al, 2005)¡£RG-I1ÊÇÖ÷ÒªµÄGS,µ«Æä½á¹¹ÌØÕ÷ÓëRG-I²î±ð½Ï´ó£¬ÆäÖ÷Á´ÎªHG½á¹¹£¬º¬ÓÐAºÍBÁ½¸ö²àÁ´£¬Ã¿¸ö²àÁ´º¬ÓÐ9¸ö»ò10¸öÌDzлùͨ¹ýÖÁÉÙ22ÖÖÌÇÜÕ¼ü×éÉí·ÖÖ§¡£¸ßµÈÖ²Îï¹û½ºµÄÁí-ÖÖGSÊÇľÌǾ۰ëÈéÌÇÈ©Ëá(xylogalacturonan, XGA)£¬ËüÊÇÔÚHG¹Ç¼ÜÉÏGalpAµÄO-3 ͨ¹ýB-ÌÇÜÕ¼üÓëľÌÇÁ¬½ÓËùÐγɵÄÒ»ÖÖ·ÖÖ§½á¹¹¡£

    2.ÉÅʳÏËά¹û½ºµÄ¿¹Ö×Áö»îÐÔ

          À´Ô´ÓÚÏàéÙ¡¢Æ»¹û¡¢ÂíÁåÊí¡¢¸ÊÊíµÈÖ²ÎïµÄÉÅʳÏËά¹û½º¾ù¾ßÓп¹Ö×Áö»îÐÔ(Bergman, Djaletti, Salman & Bessler, 2010; Zhang, Mu, & Zhang, 2012)¡£DF-PecµÄ¿¹Ö×Áö×÷ÓûúÖÆ¿ÉÄÜÓëÒÖÖÆÖ×ÁöÉú³¤(Chengetal,2011)¡¢¿¹Í»±ä±£»¤×÷ÓÃ(Hensel & Meier, 1999)¡¢ÒÖ¾úºÍÃâÒßÔöÇ¿»îÐÔ(Chen et al, 2006; Georgiev et al,2012)¡¢µ÷¿Øת»¯Ïà¹ØmicroRNAºÍ°©»ùÒòµÈÓйØ¡£ÓÉÓÚDF-Pec »ù±¾ÉÏÔÚ³¦µÀÄÚÆð×÷Óã¬Òò¶ø£¬Æ俹Ö×Áö»îÐÔÑо¿¼¯ÖÐÓڽ᳡°©(Cheng et al, 201 1; Schmidgall &Hensel, 2002)¡£

          ¹û½ºµÄÒÖ°©×÷ÓÃÖ±½Ó»ò¼ä½ÓµØÓëÒÖ¾ú×÷ÓÃÓйØ¡£¹Ñ¹û½ºÄܹ»ÒÖÖƳ¦µÀÓк¦¾úÉú³¤£¬¶øÀûÓÚË«Æç¸Ë¾ú(e.g. Bifidobacteria and Lactobacillus)µÈÒæÉú¾úµÄÉú³¤£¬¹Ñ¹û½º×÷ΪÒæÉúÔªµÄЧ¹ûÓÅÓÚ¹û½º(Avivi-Green, Polak-Charcon, Madar &Schwartz, 2000a ; Olano-Marin, E., 2002)¡£¹û½ºÔڽ᳦Öз¢½Í±¬·¢Ò»Ò»Ð©¶ÌÁ´Ö¬·¾Ëá(Short-chain ftty acids, SCFA)£¬ÀýÈ綡ËᣬÄÜʹ³¦µÀ»Ö¸´Õý³£¾úȺ£¬²¢ÇÒͨ¹ýÔö½ø½á³¦Ï¸°ûµ÷Íö¡¢¼ÓËÙÒþÎÑϸ°ûÖÜת¶øÒÖÖƽ᳦°©(Avivi-Green,C,Polak-Charcon, S, Madar, Z. & Schwartz, 2000b; Rao, Chou, Simi, Ku, & Reddy,1998)¡£Æ»¹û¹û½ºµÄ¿¹°©×÷ÓûúÖÆ°üÀ¨½µµÍ·à±ãϸ¾úÖÐø(¦Â-ÆÏÌÑÌÇÈ©ËáÜÕø¡¢¦ÂÆÏÌÑÌÇÜÕøºÍÉ«°±Ëáø)µÄˮƽ(Ohkami et al, 1995)¡¢ ½µµÍ·¢°©¼ÁÑõ»¯Å¼µª¼×ÍéÓÕµ¼½á³¦Ö×ÁöµÄ¶à·¢ÐÔ(Ohnoetal,2000)¡¢Ïû³ý×ÔÓÉ»ù(Urias-Oronaetal,2010)¡¢¼õÉÙDNA¼ÓºÏÎïˮƽ(Zunft, Goldin-Lang, & Dongowski, 1997)µÈ¡£Å¼µª¼×Íé( azoxymethane, AOM)Äܹ»ÓÕ·¢´óÊó½á³¦°©,ʹµÃijЩmicroRNA ( miR-16,miR-19b, miR-21, miR26b, miR27b, miR-93, and miR-203µÈ)±í´ïÒì³££¬¸»Óж಻±¥ºÍÖ¬·¾Ëá( n-3 polyunsaturated ftty acids (PUFAS))µÄÓãÓÍÄܹ»ÒÖÖÆ microRNA½éµ¼µÄÖ×Áöת»¯¡£¹û½ºÄܹ»ÔöÇ¿ÓãÓ͵ÄÒÖ°©×÷Óã¬ÔÚmRNAºÍÂÑ°×ÖÊˮƽÉÏÒÖÖÆPTK2B,PDE4B,andTCF4µÈ°©»ùÒòÔÚ°©Ö¢ÔçÆÚµÄ×÷ÓÃ(Shahetal,2011)¡£È˲ιû½ºPG-F2¿ÉÒÖÖÆHelicobacter pylori¶ÔθÉÏƤϸ°ûµÄ𤸽£¬¿ÉÍûÔ¤·Àθ°©µÄ±¬·¢(Lee, et al, 2006)¡£

          ±ðµÄ£¬¹û½ºµÄ¿¹Ö×Áö»îÐÔ»òÐíͨ¹ýÔöÇ¿ÃâÒßϸ°û»îÐÔ¶øʵÏÖ(Chengetal,2011; Jeonet al, 2011)¡£ÀýÈ磬¸ßÀöºì²Î¹û½º(Korean Red Ginseng Pectin, KRG)KRGÄÜÔöÇ¿NF-KB;¾¶¶ø»î»¯¾ÞÊÉϸ°û¡¢ÒÖÖÆËèϵÒÖÖÆÐÔϸ°û¶øÔöÇ¿Tϸ°û»îÐÔ(Choi et al, 2008; Jeon et al, 2011)¡£È˲ιû½ºGPÄܼõÈõL-929ϸ°ûµÄǨÒÆÄÜÁ¦(Fan et a.,2010),Õâ»òÐíÄܹ»½µµÍÖ×Áöϸ°ûµÄתÒÆDZÄÜ¡£»ýÑ©²Ý¹û½º¾ßÓд̼¤Tϸ°ûºÍBϸ°ûÔöÖ³µÄÃâÒß»îÐÔ£¬ÕâÖÖ»îÐÔµÄÇ¿ÈõÊÜõ¥»¯¶ÈµÄÓ°Ïì(Wang, Dong,Zuo, & Fang, 2003)¡£

          3.¿ÉÉúÎïÀûÓõĸÄÐÔ¹û½º

          ͨ¹ýËáºÍ¼î(Glinsky & Raz, 2009; Platt & Raz, 1992)¡¢¼ÓÈÈ(Cheng et al.2011;Jackson et al, 2007)¡¢ÉäÏß(Kang et al, 2006) »òø´¦Àí(Olano-Martin, E.,. 2003;Zhang,Xu,Giao,Yan,&Yang,2013)µÈÊֶνµµÍ¹û½º·ÖÁËÁ¿ºÍõ¥»¯¶È¶ø»ñµÃµÄ¸ÄÐÔ¹û½º¾ßÓп¹Ö×Áö»îÐÔ¡£ÀýÈç, pH¸ÄÐÔ¸ÌéÙ¹û½º(pH-modified citrus pectin, MCP)ÔÚÒÖÖÆÖ×ÁöÉú³¤¡¢ÒÖÖÆÖ×ÁöѪ¹ÜÐÂÉú¡¢¿¹×ªÒƵȷ½Ãæ¾ùÓлîÐÔ£¬ÈÈ´¦Àí¹û½º(heattreatedcitruspectin,HTCP)¾ßÓÐÓÕµ¼Ç°ÁÐÏÙ°©Ï¸°ûµ÷ÍöµÄ»îÐÔ(Jacksonetal,2007)£¬¶øÈȸÄÐÔµÄÈ˲ιû½º¾ßÓÐÒÖÖƽ᳦°©Ï¸°ûHT-29µÄ»îÐÔ(Chengetal,2011)¡£Í¨¹ý20 kGyµÄyÉäÏß´¦Àí¹û½º£¬²»µ«²»»á±¬·¢Ï¸°ûÖÂÍ»±äЧӦ£¬²¢ÇÒÄܹ»ÒÖÖÆHT-29µÈ¶àÖÖÖ×Áöϸ°û(Kang et al, 2006)¡£

          ¹û½ºÄܹ»ÔÚÌåÄÚ·¢»Ó¿¹Ö×Áö»îÐÔµÄÇ°ÌáÊÇ£¬ÐèÒªÓÐÒ»-¶¨µÄÉúÎïÀûÓöÈ£¬¼´Äܹ»½øÈëѪҺѭ»·£¬±¾ÎĽ«ÕâÀà¸ÄÐÔ¹û½ºÍ³³ÆΪ¿ÉÉúÎïÀûÓùû½ºÆ¬¶Î( Bioavailablemodified pectin fragments, BMPFs). MCPÊÇÕâÀà·Ö×ÓµÄÖ÷Òª´ú±í£¬ËüÊÇͨ¹ýËá¼îË®½âÌìÈ»CP¶ø»ñµÃµÄÒ»ÖÖ·Ö×ÓÁ¿¸üС¡¢õ¥»¯¶È¸üµÍ¡¢·ÖÖ§½á¹¹¸ü¶ÌµÄ¹û½ºÑÜÉúÎï(Nangia-Makker et al, 2002; Zhang, 2006)¡£ÎªÊ²Ã´CPûÓÐÒÖÖÆÖ×ÁöתÒƵĻîÐÔ£¬¶øMCP¾ßÓÐÕâÒ»»îÐÔ?Ê×ÏÈ£¬Ë®½âʹ¹û½º·Ö×ÓµÄÎïÀíÐÔÖʱ¬·¢±ä¸ï£¬Èܽâ¶ÈÔö¼Ó¡£¼îʹCP¹Ç¼ÜHGͨ¹ýB-Ïû³ý×÷ÓöøËõ¶Ì,õ¥»¯¶È´ÓԼĪ80%½µµÍÖÁ10%

    ÒÔÏ£¬¹û½ºÆ¬¶ÎÈܽâ¶ÈÔö¼Ó(Eliz, Hothkiss, Fishman, & Rode, 2006; Zhang et al,2010)¡£Æä´Î£¬·Ö×ӵġ°Ò©Ð§»ùÍÅ¡±µÄº¬Á¿ÓëÂþÑÜ״̬ÔÚË®½âÀú³ÌÖб¬·¢¸Ä±ä¡£ÓÉÓÚß»à«ÌÇÐγɵÄÌÇÜÕ¼ü±ÈßÁà«ÌÇÌÇÜÕ¼ü¶ÔËá¸üÃô¸Ð£¬Òò¶ø¹û½ºµÄRG-IµÄľ¹Ñ¾ÛÌÇ¡¢°¢À­²®¹Ñ¾ÛÌǵÈƬ¶ÎµÄËá½âËÙÂÊ´óÓÚ°ëÈé¹Ñ¾ÛÌÇƬ¶Î£¬ËáʹµÃ¹û½ºµÄ¹Ç¼ÜºÍë·¢ÇøÁ´³¤Ëõ¶Ì£¬²¿·Ö°¢À­²®°ëÈé¹Ñ¾ÛÌÇÖеİ¢À­²®ÌDZ»Ë®½â£¬°ëÈé¹Ñ¾ÛÌDZ»¸»¼¯£¬´Ó¶øÔöÇ¿ÁËËùν¡°Ò©Ð§»ùÍÅ¡±--¶Ë¦Â-°ëÈéÌÇÜÕÓëÆä°Ðµã°ëÈéÌÇÄý¼¯ËØ-3( galectin-3, Gal-3)µÄÌÇʶ±ð½á¹¹³Ç(carbohydrate rcognition domain, CRD)¼äµÄ×÷ÓÃ(Krall & McFeeters, 998; Mrris, Gromer, Kirby, Bongaerts, & Gunning,2011)¡£¸ßõ¥¹û½ºÔÚË®ÖгÊÊèˮ͞ÛÎï»òÄý½º£¬¶øMCP·Ö×ÓÊÇ¿ÉÈܵÄ£¬ÆäÄ©¶Ë¦Â-°ëÈéÌDzлùÒ×ÓÚ¡°·ºÆð"¸ø°Ð·Ö×ÓGal-3.ÁíÒ»¸öÓ°ÏìMCPÒ©´ú¶¯Á¦Ñ§ÐÔÖʵIJÎÊýÊÇ·Ö×ÓÁ¿¡£·Ö×ÓÁ¿¿ÉÄÜ»á´ÓÎüÊÕºÍÏû³ýÁ½·½ÃæÑ붨×ÅѪҩŨ¶È(Zhang,Gao,Shi,& Zhang, 2007)¡£ MCP ·Ö×ÓÁ¿ÔÚ3 000-60 000¹æÄ£(Gao et al, 2012b;Ramachandran et al, 201 1; Zhang et al, 2007;)¡£Ò»ÖÖÉÌÒµ»¯µÄBMP5---GCS-100,Æä·Ö×ÓÁ¿Ô¼ÄªÎª10 kDa¡£

          ÉúÎïÀûÓöȵÄÆéá«ÓëÒ©ÎïµÄÀí»¯ÐÔÖʺÍÎüÊÕ»úÖÆÓйØ¡£BMPFs µÄÀí»¯ÐÔÖÊÖ§³Ö¸ÄÐÔʹÆä¸üÈÝÒ×±»Ð¡³¦Î¢ÈÞëÎüÊÕ¡¢²¢Ö±½Ó½øÈëѪ¹Ü½ø¶øÔÚÌåÄÚ´æÁôµÄ¼ÙÉè¡£¿ÉÊÇ£¬¾¡¹ÜÔÚ¶ÔMCPÓÃÓÚÖؽðÊôÅŶ¾ºÍÒÖÖÆÖ×Áö·ÎתÒƵÄÑо¿Öоù±êÃ÷µÍõ¥»¯¶ÈµÄ¹û½ºÄܹÄÎüÊÕ(Eliaz, L, 2003; Pienta et al, 1995; Wai, AIKarkhi, & Easa,2010)£¬È»¶øȱ·¦×ã¹»µÄÌåÄÚʵÑéÖ¤¾ÝÖ¤Ã÷´øÓиºµçºÉ½Ï¶àµÄ·Ö×Ó¿ÉÒÔ±»ÎüÊÕ¡£¿Ú·þÒ©ÎïÄÜ·ñ±»ÎüÊÕÒªº¦ÊÇÄÜ·ñ±»Ð¡³¦ÉÏƤϸ°ûÎüÊÕ»òÕß͸¹ý½ôÃÜÁ¬½Ó(intracllular tight junction)¡£³£½ÓÄÉCaco-2 Ë«ÊÒÄ£ÐÍÑо¿Ò©ÎïÎüÊÕ£¬ÓôËÄ£ÐͶÔMCPµÄ¿çĤÎüÊÕ½øÐеÄÑо¿±êÃ÷½öÓйû½ºµÄÖÐÐÔ¹ÑÌÇƬ¶Î´©Ô½ÁËĤ£¬¶ø¸»ÓаëÈéÌÇÈ©ËáµÄ¹û½ºÆ¬¶ÎûÓÐ͸¹ýĤ(Courts, 2013)¡£MaxwellµÈ(Maxwell, Belshaw,Waldron, & Morris, 2012; Morris, Belshaw, Waldron, & Maxwell, 2013)±È½ÏÁ˸ÄÐÔ¹û½ºÓëÆϾÛÌÇÔÚÀí»¯ºÍÒ©´ú¶¯Á¦Ñ§ÐÔÖÊ·½ÃæµÄÒìͬ£¬ÈÏΪ¹û½ºÆ¬¶Î¿Éͨ¹ý±»¶¯ÎüÊÕ»òϸ°û(ÀýÈ磬С³¦ÉÏƤϸ°û¡¢GALT¡¢Mϸ°û)Ö÷¶¯²¶»ñÁ½ÖÖ·½·¨¶øÐÞÊΡ¢×ªÔ˺ÍÊÍ·Å¡£ÓÐЩÉúÎï´ó·Ö×Ó¿ÉÒÔ±»ÊÜÌåʶ±ð¶øÄÚÍÌ£¬ÀýÈ磬B-ÆϾÛÌÇÄܹ»±»¾ÞÊÉϸ°ûµÄdectin-1 תÔË(Brown et al, 2002; Ozment, Goldman, Kalbfleisch, &Williams, 2012; Weigel, & Yik, 2002)¡£BMPFs ÊÇ·ñ±£´æ¾­ÓÉGal-3½áºÏ±»×ªÔËÖÁ

     Ï¸°ûÄڵĿÉÄÜ?ÉÏƤϸ°ûϸ°ûĤÉÏijЩÌÇÂѰ׿ÉÒÔ±»Gal-3ʶ±ð²¢ÄÚÍÌ(Gaoetal, 2012a)¡£Òò´Ë£¬±£´æBMPFs±»Gal-3½áºÏ¶ø±»Ï¸°ûÄÚÍ̵ĿÉÄÜÐÔ¡£Èç¹û¸Ã¼ÙÉ轨Á¢£¬Ñо¿Äܹ»±»Gal-3×ÊÖú¶øÄÚÍÌÅäÌåµÄ»úÖƺÍÅäÌåµÄ½á¹¹Ìص㣬¹ØÓÚÌá¸ßÅäÌåµÄÉúÎïÀûÓöȺÍÉúÎï»îÐÔÄܹ»´øÀ´ÓÐÒæµÄ½á¹û¡£±ðµÄ£¬ÔÚ¸Îϸ°ûÍâòÓдó×ÚµÄC-ÐÍÄý¼¯ËØÍÑÍÙÒºËáÌÇÂÑ°×( asialoglycoprotein rceptor, ASGP-R)ÄÜÒÆתÔËһЩ´øÓаëÈéÌÇÄ©¶ËµÄÌÇÂÑ°×½øÈë¸Îϸ°û£¬¿¼Âǵ½BMPFs¼òÖ±Äܹ»ÒÖÖƸΰ©(Liu et al, 2008; Straube et al, 2013; Zhang et al, 2010),Òò´Ë£¬BMPFsÔÚ¸ÎÔàÊÇ·ñÄܹ»±»ASGP-RתÔËÖµµÃ½øÒ»Ò»²½Ì½ÌÖ¡£

          BMPFsËäÈ»¿ÉÒÔͨ¹ý¿Ú·þÒÔÍâµÄ;¾¶¸øÒ©( ÀýÈç×¢Éä)£¬¿ÉÊÇÓÉÓÚBMPFsÇ×Ë®ÄÜÁ¦Ç¿£¬Ëü͸¹ýĤϵͳµÄÄÜÁ¦ÉÐÎÞ·¨È·ÈÏ¡£Gal-3 Äܹ»ÔÚϸ°ûĤÍâò¡¢Ï¸°ûÖʺÍϸ°ûºËÖбí´ï,Ò²¿ÉÒÔ±»Êͷŵ½ÑªÒºÖжø·¢»Ó×÷Óᣲî±ðÑÇϸ°ûλÖõÄGal-3¾ßÓвî±ðµÄ¹¦Ð§¡£Gal-3µÄÒÖÖƼÁBMPFsÄܹ»ÔÚÄĸöÑÇϸ°ûλÖÃÆð×÷Óã¬Ä¿Ç°µÄÑо¿Éв»³ä·Ö¡£

          4. BMPFsµÄ¿¹Ö×Áö»úÖÆ

          ±¾ÎÄÖصãÒÔMCPΪÀý²ûÊÍBMPFsµÄ¿¹Ö×Áö»úÖÆ¡£MCPÔÚÒÖÖÆÖ×ÁöÉú³¤.Ѫ¹ÜÐÂÉúºÍתÒƵȶà¸ö»·½Ú¾ùÄÜÆð×÷Ó㬶ÔÇ°ÁÐÏÙ°©µÄ·ÎתÒÆ¡¢ÐþÉ«ËØÁöµÄ·ÎתÒÆ¡¢½á³¦°©µÄ¸ÎתÒÆ¡¢ÈéÏÙ°©¡¢Ñª¹ÜÈâÁöµÄÖÎÁƵȾùÓÐÑо¿±¨µÀ(Johnson et al,2007; Liu et al, 2008; Nangia-Makker et al, 2002; Platt et al, 1992; Pienta et al,1995),¿¹Ö×Áö»úÖÆÉæ¼°µ½¶ÔÖ×Áö¾ÞϸµÄÒÖÖÆ¡¢¶Ô»¯ÁÆÒ©ÎïµÄÔöÃô¡¢¶ÔÖ×ÁöתÒÆÀú³ÌµÄÒÖÖƺͶÔÃâÒßϸ°ûµÄµ÷¿ØµÈ¼¸¸ö·½Ãæ¡£

          4.1¸ÄÐÔ¹û½º¶ÔÖ×ÁöÉú³¤µÄÒÖÖÆ×÷ÓÃ

          ¾¡¹Ü²¿·Ö±¨µÀÏÔʾ£¬BMPFs ¶ÔÖ×Áöϸ°û¼ÈûÓÐϸ°û¶¾ÐÔ£¬Ò²²»¿ÉÒÖÖÆÆäÉú³¤£¬¿ÉÊÇ£¬ÓÐЩʵÑéͨ¹ý¶¯ÎïÄ£ÐÍÒѾ­ÊӲ쵽MCPÄÜÒÖÖƶàÖÖÀàÐÍʵÌåÁö¾ÞϸµÄÏÖÏó¡£ÄÜ·ñ±¬·¢ÒÖÖÆ×÷ÓûòÐíÓëÖ×Áö×éÖ¯ÀàÐÍ»òBMPFsµÄÆ÷¹ÙÂþÑÜ»òÑÇϸ°ûÂþÑÜÓйØNangia-Makker et al, 2002; Platt et al, 1992; Zhang et al, 2010)¡£Raz Ñо¿×é(Nangia-Makker et al, 2002; Platt et al, 1992)ÈËÔÚÓ¦Óý᳦ÏÙ°©LSLiM6¡¢Èé

    ÏÙ°©MDA-MB-435µÈ¶ñÐÔ¸ßתÒÆÖ×Áöϸ°ûϵÑо¿MCP¿¹Ö×ÁöתÒƵÄÊÔÑéÖÐÊӲ쵽MCPÓмõÂýÖ×ÁöÉú³¤ËٶȵÄ×÷Óá£HayashiµÈ(Hayashi, Gillen, & Lott, 2000)Ñо¿ÁËMCP¹ØÓÚÒÆÖ²Á˽᳡-25 (colon-25)Ö×ÁöµÄbalb-cСÊóÖ×Áö¾ÞϸÓëÖØÁ¿µÄÓ°Ïì¡£´¥Õïʱ´¥Ãþµ½Ö×ÁöºóµÚ20Ì죬µÍ¼ÁÁ¿×é(0.8 g/L)ºÍ¸ß¼ÁÁ¿×é(1.6 g/L)¸øҩСÊóÆäÖ×Áö¾Þϸ¶¼ÏÔÖøµØ±È±ÈÕÕ×éС¡£ÔڵͼÁÁ¿MCP¸øÒ©×飬38%µÄСÊóÖ×Áö¾Þϸ¼õС(p<0.02). ÆäÖи߼ÁÁ¿×éÔ½´´ÔìÏÔ( 70%µÄСÊóÖ×Áö¼õÉÙ£¬p<0.001)¡£¶ÔÖ×ÁöµÄÒÖÖÆ¿ÉÄÜÉæ¼°-Ò»¸ö»ò¶à¸ö»·½Ú:ÀýÈ磬·¢°©Àú³Ì(Liu et al,2010; Shah et al, 2011)¡¢Ö×Áöϸ°ûÔöÉú¡¢µòÍö;¾¶µÈ¡£

          Ç°ÎÄÒѾ­ÂÛÊöÁËDF-pec¶Ô·¢°©Àú³ÌµÄÒÖÖÆ×÷Óá£BMPFs Ò²Äܹ»ÒÖÖÆ·¢°©Àú³Ì¡£Mucin¼Ò×åµÄÂÑ°×ÊÇ-ÖÖ¸»º¬O-ÌÇÁ´µÄÉÏƤϸ°û±í´ïµÄÌÇÂÑ°×£¬ÆäÍâòµÄÌÇÁ´ÊÇGal-3µÄÅäÌå¡£Gal-3 Äܹ»ÔÚת¼ˮƽEͨ¹ý¼¤»îAP-1 (a transcriptionfactor) ¶øÉϵ÷MUC2(Song et al, 2005; Wong et al, 2011)¡£MUC2µÄÒì³£±í´ïÓë½á³¦°©µÄ±¬·¢¼°×ªÒÆÏà¹Ø¡£Òò¶ø£¬BMPFs ÓпÉÄÜͨ¹ýÒÖÖÆGal3¶øÒÖÖÆMUC2Ïà¹ØµÄ½á³¦°©µÄ±¬·¢ºÍתÒÆ¡£ÁíÍ⣬½á³¦Ñ×Óë½á³¦°©±£´æ¸ß¶ÈÏà¹ØÐÔ£¬¹û½ºÄܹ»Í¨¹ýÒÖÖÆ·¢Ñ׶øÒÖÖÆ·¢°©¡£NF-KBÊÇʹµÃLPSÓÕ·¢½á³¦Ñ×ת»¯Îª½á³¦°©µÄ-Ò»¸öÒªº¦ÒòËØ¡£À´×ÔÓÚÆ»¹û¹û½ºµÄ°ëÈé¹Ñ¾ÛÌÇÄÜͨ¹ý×÷ÓÃÓÚLPS/TLR4/NF-KB;¾¶¶øÒÖÖÆ·¢°©(Liu et al, 2010)¡£

          MCP¿ÉÄÜͨ¹ýÓ°ÏìÖ×Áöϸ°ûµÄϸ°ûÖÜÆÚ¶øÒÖÖÆÖ×Áöϸ°ûÔöÖ³¡£MCPʹÈËÇ°ÁÐÏÙ°©Ï¸°ûJCA-1Éú³¤¼õÉÙ¡¢[H]à×ऽøÈëDNAµÄËÙÂʼõÈõ¡¢Ï¸°ûÖÜÆÚËØB¡¢p34ºÍcdc2»ùÒòµÄ±í´ïFµ÷,Æä»úÖÆ¿ÉÄÜÓëϸ°ûÖÜÆÚµÄÔçG2ÆÚÓйØ(Hsich&Wu,1995)¡£MCPÒÖÖÆÖ×Áö¿ÉÄÜÓëGal-3ÓйØ£¬¶øGal-3ÄÜϵ÷cyclin AºÍcyelin EµÄ±í´ïˮƽ£¬¿ÉÊǶÔMCP¶Ôcyclin AºÍcyelin EµÄ±í´ïˮƽÓëGal-3¼ä¹ØÁªµÄ±¨µÀÉÐδ¼ûµ½¡£

          ÒÖÖÆÖ×ÁöÉú´æÐźŻòÕßÓÕ·¢ÆäµòÍöÐźžùÄÜÓ°ÏìÖ×ÁöÉú³¤¡£Gal-3 ¼ÈÓëÉú´æÐźÅMAPK;¾¶¡¢Wnt;¾¶ÓйØ(Lee, Lin, Chang. & Lo, 2013; Maxwell et al, 2012;Song et al, 2012)£¬Ò²ÓëµòÍö;¾¶ÓйØ(Harazono, Nakaima, & Raz, 2013)¡£¸ÄÐÔ¹û½ºPectaSol-CÄܹ»ÓÕµ¼LNCaPºÍPC3ϸ°ûµÄµ÷Íö(Yan, & Katz, 2010)¡£WBÆÊÎöÈ·ÈÏMCPÄܹ»ÒÖÖÆPC3ºÍCASP11Ç°ÁÐÏÙ°©Ï¸°ûMAPK;¾¶µÄ»î»¯£¬²¢ÇÒÔöÇ¿ÏÂÓδٵòÍöÂÑ°×BimµÄ±í´ïˮƽ¡£Òò´Ë£¬MCP¶ÔÖ×ÁöµÄÒÖÖÆ¿ÉÄܼÈÓëÖ×ÁöÉú

    ´æ;¾¶ÒÖÖÆÓйØ£¬Ò²ÓëµòÍö;¾¶»î»¯ÓйØ¡£¸ÄÐÔ¹û½ºÄÜ·ñÓÕµ¼µòÍö£¬ÓëÆä½á¹¹ÌØÕ÷ÓйØ(Jacksonetal.2007)¡£Òò´Ë£¬ÐèÒª½ø:-²½´Ó¹¹Ð§¹ØϵµÄ½Ç¶ÈÑо¿¹û½ºÓëµòÍö¼äµÄ¹ØÁª¡£

    4.2¸ÄÐÔ¹û½º¶Ô»¯ÁÆÒ©ÎïµÄÔöÃô×÷ÓÃ

          ijЩÖ×Áöϸ°ûÄܹ»¶Ô¿¹»¯ÁÆÒ©Îï¶ø²»±¬·¢µ÷Íö,Òò´ËÐèҪѰÕÒ»¯ÁÆÔöÃô¼ÁÀ´½â¾öÕâÒ»ÁÙ´²ÉϵÄÄÑÌ⣬¶øBMPFsÊÇ»¯ÁÆÔöÃô¼ÁµÄÖØÒªºòÑ¡·Ö×Ó¡£Gal-3 ÓÐÀûÓÚά³ÖÖ×ÁöÄÍÒ©ÐÔ±íÐÍ£¬Òò¶øÕë¶ÔGal-3 µÄÒÖÖƼÁÄܹ»ÄæתÖ×ÁöÄÍÒ©ÐÔ(Fukumori,Kanayama, & Raz, 2007)¡£ChauhanµÈ(Chauhan et al, 2005)½ÓÄÉÉÌÆ·À´Ô´µÄ¸ÄÐÔ¸ÌéÙ¹û½ºGCS-100ÓÕµ¼¶ÔµØÈûÃ×ËÉ¡¢ÃÀ·¨ÂØ»ò°¢Ã¹ËØÓп¹ÐÔµÄÈËÀà¶à·¢ÐÔ¹ÇËèÁöϸ°ûϵµÄµòÍö¡£ÆñÂÛÊǵ¥¶ÀʹÓÃGCS-100,ÕÕ¾ÉÓëµØÈûÃ×ËÉÊÊÓö¼Äܹ»ÒÖÖÆÖ×ÁöÉú³¤¡¢¿Ë·þ¿¹Ò©ÐÔ£¬²¢ÇÒÌá¸ß²¡È˶ñÐÔѪ°©µÄÉú´æÆÚ¡£ÓÉÓÚBMPFsÄÜÏÔÖøÔöǿϸ°û¶Ô»¯ÁÆÒ©ÎïµÄÃô¸ÐÐÔ,ÕâÖÖ×éºÏ¸øÒ©¼Æ»®ÓÐÖúÓÚÔÚÁÙ´²ÉϼõÉÙÓж¾µÄ»¯ÁÆÒ©Îï¼ÁÁ¿£¬ÑÓ»ºÖ×ÁöÄÍÒ©ÐԵı¬·¢(Chauhan et al, 2005; Hossein, Keshavarz, Ahmadi,& Naderi, 2013; Jiang, Eliaz, & Sliva, 2013; Lu, Wang. & Liu, 2013; Wang, & Liu,2011)¡£GCS-100µÄÕâÖÖ»¯ÁÆÔöÃô×÷ÓÿÉÄÜÓëµòÍöµÄÍâÔÚ;¾¶ºÍÄÚÔÚ;¾¶¶¼Ïà¹Ø(Chauhan et al, 2005)¡£

          »¯ÁÆÒ©Îï¶Ô¿¹×÷ÓûúÖÆÖ®Ò»ÊÇÓÉÓÚGal-3 ×ÌÈÅÁËTRAIL (Tumor necrosisfactor-related apoptosis-inducing ligand) ÓëÊÜÌåDR4ºÍDRS¼äµÄÏ໥×÷Ó㬽ø¶øÎÞ·¨ÐγÉÄܹ»ÓÕµ¼µ÷ÍöµÄ¸´ºÏÎïDISC (death-inducing signaling complex)¶øÒýÆðµÄ(Mazurek et al, 2012)¡£BMPFs »òÐíÄܹ»ÔÚϸ°ûÍâÓëGal-3Ïà½áºÏ£¬ÖÆÖ¹ÁËGal-3¶ÔTRAILÓëDR4/DRSµÄ×ÌÈÅ×÷Ó㬴ӶøʹµÃÖ×Áöϸ°û¶Ô»¯ÁÆÒ©ÎïÓɲ»Ãô¸Ð±äΪÃô¸Ð¡£:

    4.3¸ÄÐÔ¹û½º¶ÔÇÖÏ®ÓëתÒƵÄÒÖÖÆ

          ÇÖÏ®ÓëתÒÆÉæ¼°Ö×Áöd¹ÜÐÂÉú¡¢Ê§³²µòÍöÌÓÒÝ¡¢Ñª¹ÜÄÚƤϸ°û𤸽µÈµÄ¶à»·½Ú£¬Gal-3 ¾ù¼ÓÈëÕâЩ»·½Ú¡£½ÓÄÉ×¢ÉäµÄÒªÁì(Platt et al, 1992)¡¢ ¿Ú·þMCPµÄÒªÁì(Pienta et al, 1995)ÒÔ¼°ÁÙ´²ÊµÑé(Guess et al, 2003)£¬¶¼Ö¤Ã÷MCPÔÚÌåÄÚ¾ßÓÐ

      ÒÖÖÆÖ×ÁöתÒƵĻîÐÔ¡£Platt µÈ(Platt et al, 1992)×îÔ籨µÀ£¬×¢ÉäMCP¿ÉÃ÷ÏÔ¼õÉÙСÊóÖ²ÈëB16-F1ÐþÉ«ËØÁöϸ°ûºóµÄ·Î²¿¼¯Â䣬¶øCPÔòÔö¼ÓÆä·Î²¿¼¯Âä¡£MCP¿ÉÒÖÖÆB16-F1ÐþÉ«ËØÁöϸ°û𤸽µ½²ãð¤Á¬ÂѰ׺ÍÍÑÍÙÒºËáÌ¥ÇòÂÑ°×ÓÕµ¼µÄͬÐ;ۼ¯£¬µ«CP²»¾ßÓÐÕâÖÖÒÖÖÆ×÷Óá£Á½ÖÖÌǶ¼ÄÜÒÖÖÆB16-F1ÐþÉ«ËØÁöϸ°ûÔÚ°ë¹ÌÌåÅàÑø»ù£¬ÈçÇíÖ¬ÌÇÖеķÇêµØÒÀÀµÐÔÉú³¤(Nangia-Makkeret al, 2002)¡£ÕâÒ»½á¹û±êÃ÷£¬ÓÉϸ°ûÍâòµÄGal-3½éµ¼µÄÌÇʶ±ð¿ÉÄܼÓÈëϸ°û-ECMÏ໥×÷Ó㬲¢ÔÚÌåÄÚÖ×Áöϸ°û˨ÈûºÍϸ°ûêµØÒÀÀµÐÔÉú³¤ÖÐÆðÖØÒª×÷Óá£

          ÔÚתÒÆÀú³ÌÖб¬·¢Ê§³²µ÷ÍöÌÓÒÝ£¬¹ØÓÚתÒÆÀÖ³ÉÌرðÒªº¦¡£Gal-3 ÊÇÒ»-ÖÖ¿¹µ÷ÍöÂÑ°×£¬Í¨¹ý¹ý±í´ï£¬ËüÄܹ»Ê¹Ï¸°ûÖÜÆÚÔÚGiÆÚ±¬·¢×èÖÍ£¬Ïµ÷Gi-SÆÚϸ°ûÖÜÆÚËØˮƽ(cyclin EºÍcyclin A),Éϵ÷Ïà¹ØÒÖÖÆÂÑ°×(p21WAFIºÍp27KIP1)ˮƽ£¬Ê¹ÏßÁ£Ìå×ÔÎÈ(Kim, Lin, Biliran, & Raz,, 999 Matrrese et al, 2000¡£Òò¶ø£¬ÒÖÖÆGal-3ÓпÉÄÜÓÕ·¢Ê§³²µ÷Íö¡£Vayssade µÈ(Vayssade et al, 2010)½ÓÄÉ»ÆÇï¿û¹û½ºRG-Iʹ½ÓÄÉpolyHEMAÐü¸¡ÅàÑøµÄ¾ßÓи߶ÈתÒÆDZÁ¦µÄBI6F10ϸ°ûÍ£ÁôÔÚG2/MÆÚ£¬±êÃ÷RG-IÓпÉÄÜÓÕµ¼Ö×Áöϸ°û±¬·¢Ê§³²µ÷Íö¡£»ÆÇï¿ûRG-IʹÖ×Áöϸ°ûÍâòµÄN¸Æð¤ËØÒÔ¼°o5ÕûºÏËصıí´ïFµ÷¡£ÓÉÓÚ»ÆÇï¿û¹û½ºº¬ÓÐÏÕЩ´¿µÄ¹Ñ¾Û°ëÈéÌÇ£¬Òò¶øÕâÖÖʧ³²µ÷Íö×÷ÓÿÉÄÜÊǾ­ÓÉGal-3½éµ¼µÄ¡£²»¹ý£¬¹ØÓÚGal-3½éµ¼¿¹Ê§³²µòÍöÌÓÒÝÀú³Ì£¬ÊÇ·ñÐèÒªGal-3I½øÈë°ûÄÚ,´ó·Ö×ӵĸÄÐÔ¹û½ºÄÜ·ñ½øÈëϸ°ûÄÚ£¬ÈçºÎ½øÈëϸ°ûÄÚ£¬¼ÓÈëµ÷ÍöÄÚÔÚ;¾¶ÕÕ¾ÉÍâÔÚ;¾¶£¬BMPFs ÊÇÓÉÓÚÒÖÖÆÖ×Áöϸ°ûµÄͬÐ;ۼ¯ÕÕ¾ÉÒìÐ;ۼ¯¶ø±¬·¢¿¹Ê§³²µ÷ÍöÌÓÒݵÈϸ½ÚÎÊÌâ,ÐèÒª¸ü¶àµÄʵÑéÀ´»Ø¸²¡£

          Ö×Áöfm¹ÜÐÂÉúÊÇÖ×ÁöתÒÆÀֳɵÄÁí--Òªº¦»·½Ú.ͨ¹ý¶ÔÈËÆê´ø¾²ÂöÄÚƤϸ°û(HUVECs)ÔÚMatrigelÉÏëϸ¹ÜÐγÉÏÖÏóµÄÆÀ¼ÛÀ´Ñо¿ÔÚÌåÍâÖ×ÁôѪ¹ÜÉú³ÉÖÐMCP¶ÔGal-3½éµ¼¹¦Ð§µÄÓ°Ï졣ͨ¹ýʹÓÃBoydenСÊÒ·¨ºÍ±ê¼Ç²â¶¨·¨»®·ÖÑо¿MCP¹ØÓÚGal-3ÓÕµ¼µÄHUVECµÄÇ÷»¯×÷ÓúÍHUVEC¶ÔMDA-MB-435ϸ°ûµÄÌåÍâ½áÏàÖúÓá£ËÇιMCPµÄСÊóÆäÌåÄÚÖ×ÁöÉú³¤¡¢Ñª¹ÜÉú³É¼°×Ô·¢Ö×ÁöתÒƶ¼ÏÔÖøµØ¼õÉÙ¡£ÔÚÌåÍ⣬MCPÒÔ¼ÁÁ¿ÒÀÀµ·½·¨ÒÖÖÆHUVECµÄÐÎ̬±¬·¢(ëϸѪ¹ÜÐγÉ).MCPÒ²ÒÔ¼ÁÁ¿ÒÀÀµµÄ·½·¨ÒÖÖƱí´ïGal-3µÄMDA-MB-435¶ÔHUVECsµÄ𤸽(Nangia-Makker et al, 2002)¡£ÓÉÓÚÖ×Áöϸ°û˨Èû²¢È±·¦Ê¹Ã«Ï¸Ñª¹Ü¶ÔÆäÔì³É½ØÁ÷£¬×ªÒƵÄÖ×ÁöÔÚ°ÐÆ÷¹ÙµÄ×èÖÍ£¬ÐèÒªÖ×Áö˨Èû±í´ïµÄGal-3ÓëѪ¹ÜÇ»TF

      ¿¹Ô­( Thomsen-Friedenreich glycoantigen )¼äµÄ𤸽×÷ÓÃÀ´¸¨ÖúÍê³É(Glinskii et al,2005)£¬Òò´Ë£¬BMPFs»òÐí¿ÉÒÔÒÖÖÆÖ×Áöϸ°û˨ÈûÀú³Ì¡£Ë¨Èû²»¿ÉÐγÉÓпÉÄܽøÒ»²½µ¼ÖÂÖ×Áöϸ°û±¬·¢Ê§³²µ÷Íö¡£

          4.4¸ÄÐÔ¹û½º¶ÔÃâÒßϸ°ûµÄ×÷ÓÃ

          ¸ÄÐÔ¹û½º¶ÔÃâÒßϸ°ûµÄ×÷ÓûúÖÆÓÐÁ½ÖÖ:µÚÒ»¡¢ ×÷ΪÃâÒßµ÷Àí¼Á(biologicalresponse modifers, BRMs) (Radosavjevic et al, 2012);µÚ¶þ,ÒÖÖÆÃâÒß¼àÊÓ¡£×÷ΪBRMs£¬MCP»î»¯¶àÖÖÀàÐ͵ÄÃâÒßϸ°û¡£ÀýÈ磬MCPÒÔ¼ÁÁ¿ÒÀÀµ·½·¨»î»¯Tcϸ°ûºÍBϸ°û¡£MCP¼¤»îµÄNKϸ°ûʹ°©Ï¸°ûK562±¬·¢µòÍö(Ramachandran et al,2011)¡£Gal-3 ÓпÉÄÜʹµÃTϸ°ûÊÍ·ÅINF-yµÄÄÜÁ¦ÊÜË𣬶øGial-3µÄÅäÌåÄܹ»ÐÞ¸´ÕâÖÖÊÜËð¡£GCS-100Äܹ»Ç¿»¯CTLµÄϸ°û¶¾Ð§Ó¦£¬Ê¹ÆäÊͷŸü¶àµÄINF-y(Demotte et al, 2010)¡£

          Ðí¶àÀàÐ͵ÄÖ×ÁöÓëGal-3µÄ±í¸æ¿¢ÕýÏà¹Ø¡£Ö×Áö»¼ÕßѪҺÖÐÓÎÀëGal-3µÄŨ¶È¸ßÓÚÕý³£Öµ(lurisci et al, 2000)¡£ÓÎÀëGal-3ÄÜÒÖÖÆTϸ°ûµÄÉú³¤£¬µ¼ÖÂÆ䱬·¢µòÍö£¬Ôì³ÉÖ×ÁöµÄÃâÒßÄÍÊÜ(Peng, Wang, Miyahara, Peng, & Wang, 2008)¡£BMPFs»òÐíÄܹ»ÒÖÖÆÓÎÀëal-3¶ÔTϸ°ûµÄµ÷Íöµ÷¿Ø×÷Ó㬵«ÐèÒª½øÒ»²½µÄʵÑéÖ¤¾ÝÀ´ÑéÖ¤¡£

          4.4ÁÙ´²Ñо¿

          MCPÒѽøÐÐIIÆÚÁÙ´²Ô¤ÊÔÑé(Guess et al, 2003)£¬Ä¿Ç°Óй«Ë¾ÕýÔÚ¶Ô¸ÄÐÔ¹û½ºPectaSolCÕÐļI1ÆÚÁÙ´²ÊµÑéÊÜÊÔÕß(t:/:/www linicaltialgoy/, NCTID=NCT01681823, f.)¡£±ÊÕßδÔÚ»¥ÁªÍøÉϼìË÷µ½MCPµÄINDÉêÇëÐÅÏ¢¡£GuessµÈ(Guess et al, 2003)Ñо¿ÁË13Ãû»¼Õ߶ÔMCP (Pecta-Sol*)µÄÄÍÊÜÐÔ£¬²¢¶ÔÆäÖÐ10ÃûÊÜÊÔÕßÑо¿ÁËMCPµÄÁÆЧ£¬ÒÔÇ°ÁÐÏÙÌØÒ쿹ԭ±¶Ôöʱ¼äPSADTµÄ±ä¸ï×÷ΪÖ÷ÒªÑо¿ÖÕµã(primaryendpoint)¡£·þÓÃMCP12¸öÔºó£¬Óëδ·þÓÃÇ°±È10Ãû»¼ÕßÖеÄ7ÃûÆäPSADTÑÓ³¤(p<0.05).¸ÃÏîÑо¿½á¹ûÌåÏÖ£¬MCPÓпÉÄÜʹǰÁÐÏÙ°©»¼ÕßµÄÖ×ÁöÉú³¤ËÙÂʱäÂý¡£¿ÉÊǸÃÏîÑо¿Ñ¡ÔñµÄÊÜÊÔÕßÊýÄ¿±È-°ãµÄIÆÚÁÙ´²×¢²áËùÒªÇóµÄÊýÄ¿ÉÙ£¬Òò¶øÐèÒª½÷É÷½âÊ͸ÃÏîÑо¿µÄ½á¹û¡£¸Ã±¨¸æÖÐδÅû¶

      MCPµÄÅúºÅ£¬Î´Éè¼Æο½å¼Á±ÈÕÕ×飬δÌṩÖ×Áö±ä¸ïµÄÖ±½ÓÐÅÏ¢£¬Òò¶øÎÞ·¨½¨Á¢Ö×Áö¸ÄÉÆÓë·þÓÃMCPÖ®¼äµÄÒò¹û¹ØÁª¡£Azemar µÈ(Azemar, Hildenbrand,Haering, Heim, & Unger, 2007)¶Ô49ÃûÍíÆÚʵÌåÁöµÄ»¼Õß½øÐÐÁËÒ»´ÎÁÙ´²Ô¤ÊµÑ飬ĿµÄÊÇÆÀ¹À²¡È˶ÔMCPµÄÄÍÊÜÇé¿ö¡¢ÁÙ´²ºÍ¿¹Ö×ÁöЧ¹û¡£¾­¹ýÁ½ÂÖÖÎÁÆ£¬11/49(22.5%)µÄ²¡È˲¡ÇéÎȶ¨£¬6/49 (12.3%)µÄ²¡È˲¡ÇéÎȶ¨Áè¼Ý24ÖÜ£¬1 ¸öî¾»¼Ç°ÁÐÏÙ°©µÄ²¡ÈËÔÚÖÎÁÆ16ÖܺóÆäѪÇåPSAˮƽ½µµÍÁËÒ»°ë¡£×ÜÌå¶øÑÔ£¬¾­MCPÖÎÁƵIJ¡È˾ßÓÐÁÙ´²ÉϵÄÊÜÒ棬Ìá¸ßÁËÉú»îÖÊÁ¿¡¢¼õ»ºÁËÌÛÍ´£¬Òò¶ø£¬MCP .ÓмÌÐø½øÐÐÁÙ´²Ñо¿µÄ¼ÛÖµ¡£¸Ã±¨¸æ½ÓÄɵÄMCPÓëGuessµÈÑо¿µÄÑùÆ·²î±ð£¬Æäõ¥»¯¶ÈµÍÓÚ20%¡¢½ÓÄɼÓÈÈ´¦Àí¹ý£¬¿ÉÊÇδÌá¼°¼ÓÈÈÀú³ÌÊÇ·ñÓëHTCPµÄÖƱ¸Ïàͬ¡£

          ±ðµÄ£¬¹û½º¸øҩϵͳҲÔÚ½øÐÐ×ÅÁÙ´²Ñо¿(NCT01681823)¡£MCPµÄÁÙ´²Ñо¿²»ÏÞÓÚÖ×Áö(NCT01960946 & NCT01717248),²»¹ýÕâЩÑо¿¹ØÓÚÀí½âMCPµÄ¶¾Àíѧ¡¢Ò©´úѧµÈÐÔÖÊÓÐ×ÊÖú¡£

          5.¹¹Ð§¹ØϵÑо¿

          ¹û½º½á¹¹ºÜÊÇÅÓ´ó£¬ÒÔÆäΪԭÁÏÖƵõĸÄÐÔ¹û½º£¬¾¡¹Ü¾­¹ýÁË¿ª¶Ë´¿»¯ºÍ·Ö×飬µ«ÔÚ΢¹ÛÉÏÊDz»¾ù-µÄ¡£ÕÅÎIJ©(Zhang, 2006)ƾ¾ÝÎÄÏ×ÒªÁì(Platt et al, 1992)ÒÔÖйú²úÉÌÒµ¹û½ºÎªÔ­ÁÏ»ñµÃµÄMCPͨ¹ýHPSEC»òµçÓ¾µÈÒªÁìÖ¤Ã÷ÆäÊǵ¥ÂþÑÜ£¬¶ø½ÓÄÉÊ®ÁùÍé»ùÈý¼×»ùä廯ï§ÔÚMCPÖÐÄܳÁµí³öԼĪ1%µÄÖÐÐÔ¶àÌÇƬ¶Î¡£Gao(Gao et al, 2012b)½ÓÄÉDEAEÏËάËزãÎöÖù½«MCPµÄÖÐÐÔ¶àÌÇƬ¶Î(MCP-N)´¿»¯³öÀ´¡£ÓÉÓÚËáÐÔƬ¶ÎºÍÖÐÐÔƬ¶Î¾ßÓвî±ðµÄÐÔÖÊ£¬Òò¶ø£¬ÆÊÎöBMPFs¹¹Ð§¹ØϵÐèÒªÖƱ¸³ö½á¹¹Ô½·¢¾ùÒ»ºÍ- -ÖµĹû½ºÆ¬¶Î£¬¶ø·´¹ýÀ´, BMPFs¹¹Ð§¹ØϵµÄÑо¿ÄÜÖ¸µ¼BMPFs¸ÄÐÔÒªÁìµÄÓÅ»¯¡£

          BMPFsµÄ°ëÈéÌÇÄ©¶Ëº¬Á¿¼°ÒÔ¼°Æä·ÖÖ§´¦µÄ½á¹¹ÊÇBMPFs±£´æ¿¹Ö×Áö»îÐÔµÄÒªº¦ÒòËØ¡£Ô½À´Ô½¶àµÄÑо¿Õß¹Ø×¢¹û½ºRG-IƬ¶ÎµÄ»îÐÔ(Gao et al, 2012b;Gunning, Bongaerts, & Morris, 2009)£¬À´×Ô¹û½ºRG-IµÄƬ¶ÎÄܹ»ÓëGal-3±¬·¢Ö±½ÓµÄÏ໥×÷Óá£Ó«¹âÏÔ΢¾µ¡¢Á÷ʽϸ°ûÒǺÍÔ­×ÓÁ¦µç¾µ¼¼Êõ¾ù֤ʵ£¬¹û½ºµÄ°ëÈé¹Ñ¾ÛÌDz¿·ÖÄܹ»ÓëÈËÀàÖØ×éµÄGal-3Ïà½áºÏ(Gunning et al, 2009)¡£B-D-¾Û°ëÈéÌÇÓëGal-3¼äµÄ½âÀë³£ÊýΪ0.33 s(Gunning, Pin, & Morris, 2013)¡£»ÆÇï¿û¹û½ººÍ

    ÂíÁåÊí¹û½ºº¬Óнϸ߱ÈÀýµÄRG-IƬ¶Î(Cheng et al, 2013; Vayssade et al., 2010),ËüÃǾù¾ßÓп¹Ö×Áö»îÐÔ.GaoµÈ(Gaoetal,2012b)ÖƱ¸µÄMCP-NÊôÓÚ¹û½ºµÄAG-IÐÍƬ¶Î¡£ËûÃǽ«MCP-NÓÃa-L-°¢À­²®ß»à«ÌÇÜÕø´¦Àí£¬»ñµÃÖÐÐÔ¹û½ºÆ¬¶ÎM-MCP. M-MCPÊÇÒ»ÖÖ·Ö ×ÓÁ¿Ô¼Îª18 kDaµÄº¬ÓÐB-1,4ÌÇÜÕ¼üµÄ°ëÈé¹Ñ¾ÛÌÇƬ¶Î¡£ÓÃËá½µ½âM-MCP»ñµÃµÄ°ëÈé¹Ñ¾ÛÌDZÈAG-IÀàÐ͵Ĺû½ºÆ¬¶Î¾ßÓиüÇ¿µÄGal-3ÒÖÖÆ»îÐÔ¡£

          BMPFs¿ÉʹÖ×Áöϸ°û±¬·¢Ê§³²µ÷Íö(Glinskyetal,2009;Newlaczyl&Yu,2011)¡£µòÍö»îÐÔÓë¹û½ºµÄÄÄÀà½á¹¹Ïà¹Ø?HGƬ¶Îµ¥¶ÀÄÜ·ñÓÕµ¼Ö×Áöϸ°ûµòÍö?µ¥µ¥RG-1Ƭ¶ÎÄÜ·ñÓÕ·¢Ê§³²µòÍö?ÐèÒª¸ü¶àµÄʵÑéÐÔÑо¿À´»Ø¸²ÕâЩÎÊÌâ¡£HG¿É·ñÓÕµ¼µ÷Íö±£´æ²»-Öµı¨µÀAttari, Sepehri, Delphi, & Goliaei, 2009; Cheng etal, 2011; Jackson et al, 2007; Yan et al, 2010)¡£Jackson ±¨µÀ(Uackson et al, 2007)ͨ¹ý¶ÔCPÈÈ´¦Àí»ñµÃHTCP,ʹHG±¬·¢- -Щ¾ßÓÐÓÕµ¼µ÷ÍöµÄ»îÐÔ¡¢¶øÌìÈ»¹û½º²»¾ßÓеĽṹ£¬¿ÉÊǸýṹÉÐδ»ñµÃÊèÉ¢¡£¾­Ëá¼î¸ÄÐԵĹû½º²»¾ß±¸ÓÕµ¼µ÷ÍöµÄ»îÐÔ¡£HG¾­¹ýB-Ïû³ý¸ÄÐԻᱬ·¢²»±¥ºÍÌDzлù£¬ÕâÖÖÌDzлù»òÐíÓëMCPµÄÓÕµ¼NKϸ°ûµÄ»îÐÔÓйØ(Ramachandran et al, 2011)¡£¾­¹ýÈÈ´¦Àí£¬¹û½º»á¾­B-Ïû³ý±¬·¢´øÓл¹Ô­ÐԵIJ»±¥ºÍÌDzлùµÄ¡¢»òÕß±¬·¢ÖØÅŵĻò´øÓÐÌÇËáÀà½á¹¹ÌØÕ÷µÄƬ¶Î£¬¾¿¾¹ÄÄ-Àà½á¹¹ÌØÕ÷ÓÕµ¼Ö×Áöϸ°ûµòÍö»îÐÔ£¬ÉÐÎÞ½øÒ»²½µÄ±¨µÀ¡£

          ÏÖÓÐÎÄÏ×ÉÐȱ·¦ÒÔÖ§³Ö½ö½öRG-I²¿·ÖÆðµ½ÒÖÖÆÖ×ÁöµÄ×÷ÓÃ(Bergman et al,2010; Cheng et al, 2013; Kang et al, 2006)¡£¾¡¹ÜGal-3ͨ¹ýCRDÖ÷ÒªÓëBMPFsµÄ°ëÈé¹Ñ¾ÛÌDZ¬·¢×¨- -µÄÏ໥×÷Ó㬿ÉÊÇ£¬HG¹Ç¼Ü²¢·Ç¶ÔBMPFsµÄÒÖÖÆGal-3µÄ»îÐÔºÁÎÞТ¾´(Gao, X.,et al, 2013)¡£Ê×ÏÈ£¬Gao (Gao, et al, 2012b)ƾ¾ÝÊÇ·ñº¬ÓÐGalpAÓÃÉ«Æ×ÒªÁ콫MCPÊèɢΪÁ½×é---º¬ÓÐGalpAµÄ×é³ÆΪMCP-A£¬²»º¬GalpAµÄ×é³ÆΪMCP-N,Ç°Õ߶ÔGal-3µÄÇ׺ÍÁ¦Ô¶Ô¶¸ßÓÚºóÕß¡£Æä´Î£¬¹û½ºÆ¬¶Îº¬ÓÐGalpAµÄ¹Ç¼Ü¹ØÓÚά³Ö°ëÈé¹Ñ¾ÛÌÇÄ©¶ËƬ¶ÎµÄ¹¹ÏóÓÐТ¾´¡£ÂþÑÜÓÚHG¹Ç¼ÜÉϵĶà¸ö°ëÈé¹Ñ¾ÛÌÇÄܹ»ÓëGal-3±¬·¢Ð­Í¬Ï໥×÷ÓÃ(Gao,et al, 2013)¡£ÌÇÅäÌåÓëÄý¼¯ËؼäÈç¹û±¬·¢¶à¼ÛЧӦ£¬ÔòÆäÏ໥×÷ÓÃÇ¿¶È½«Ôö¼Ó(Witmann,V.&Pieters, RJ.. 2013)¡£BMPFs. ÉÏHG¹Ç¼Ü£¬¹ØÓÚÕâЩ°ëÈé¹Ñ¾ÛÌÇÅä»ù¶øÑÔ£¬Æ𵽡°ÇÅ¡±µÄ×÷Óá£ÔٴΣ¬ÔÚÉúÀípHϲ»¿ÉÅųýHG¹Ç¼ÜÓëGal-3µÄCRDÖ®¼ä±¬·¢µçºÉÏ໥×÷ÓõĿÉÄÜÐÔ¡£Gal-3 (uniprot/P17931) µÄCRDº¬ÓÐԼĪ135aa,λ

      Gal-3µÄC¶Ë( Seetharaman, J, 1998)¡£½ÓÄÉExpasy Êý¾Ý¿âµÄpIÔ¤²â¹¤¾ßtp:/:/web.expasy. org/compute pil)ÆÊÎö£¬±êÃ÷CRD²¿·Ö(pI=9.41) ÔÚÉúÀípHϳÊÕýµçºÉ£¬¶øHG¹Ç¼ÜÒò¸»º¬ôÈ»ù¶ø³Ê¸ºµçºÉ¡£Gao(Gao,et al, 2013)ÊӲ쵽ÁËÏÕЩ²»º¬°ëÈéÌǵĹû½º¹Ç¼ÜÓëGal-3¼äµÄÏ໥×÷Ó㬶øÕâÖÖÏ໥×÷Óò»ÊÜÈéÌǵÄÒÖÖÆ¡£Òò´Ë£¬BMPFs µÄ¹Ç¼ÜÓпÉÄÜÓëCRDÖ®¼ä±¬·¢·Çר- -µÄÏ໥×÷Óá£CRD±£´æÓëType-C×Ô¾Û¼¯ÓйصÄλµã(Lepur, Salomonsson, Nisson, & Lefler, 2012)¡£BMPFsµÄ¹Ç¼Ü»òÐí¿ÉÒÔͨ¹ýµ÷ÀíType-C×Ô¾Û¼¯¶øÓ°ÏìCRDµÄ×÷Óá£

          Gal-3×÷ΪÖ×Áö°ÐµãÔ½À´Ô½ÒýÈ˹Ø×¢£¬Ä¿Ç°ÒѾ­¿ª·¢ÁËÐí´ó¶¼ÈéÌÇÄý¼¯ËØÄý¼¯ËØÒÖÖƼÁ( galectin-3 inhibitor, Gal3I ) (Klyosov, 2012; Pieters, 2006; Zhang,2009), Gal3I ÔÚÖ×Áö¼ì²âºÍÖÎÁÆ·½ÃæÓÐמ޴óÓ¦ÓÃDZÁ¦¡£¹ØÓÚ°ÐÂÑ°×Gal3¶øÑÔ£¬¿ª·¢ÆäÒÖÖƼÁ£¬²¢·ÇÖ»ÓÐÒÔBMPFsΪÏȵ¼·Ö×ÓÕâÒ»Ìõ·¾¶£¬ËüÊܵ½ÆäËü·½ÃæµÄÌôÕ½¡£Ê×ÏÈ£¬ÀàÒ©ÐÔDruglikeness¼°³ÉÒ©ÐÔdrugabilityÊÇÆÀ¼ÛÏȵ¼·Ö×ÓÄÜ·ñ¼ÌÐø¿ª·¢³ÉΪҩÎïºòÑ¡ÎïµÄÖØÒª±ê×¼¡£ºÏ³ÉµÄGal3I¾ßÓзÖ×ӽṹȷ¶¨µÄÓÅÊÆ£¬ÆäÀàÒ©ÐԺͳÉÒ©ÐÔ±ÈBMPFs¸üºÃ¡£ÔÚÑо¿»¯Ñ§ºÏ³ÉµÄGal3IÀú³ÌÖÐ,»ñµÃÁËÐí¶àGal-3µÄCRDÓëÅäÌå¼äÏ໥×÷ÓõļÍÂÉ¡£ÕâЩ¼ÍÂɹØÓÚ½øÒ»²½ÓÅ»¯»ùÓÚBMPFsµÄ½á¹¹ÓÐËù×ÊÖú¡£»¯Ñ§ºÏ³ÉµÄGal-3IÉÐÎÞ¶¾ÀíѧÑо¿,Òò¶ø£¬´ÓÆäËüÖ²Îï¡¢ÓÈÆäÊÇʳÎï×ÊÔ´ÖÐɸѡ³öGal-3IµÄÑо¿ÒѾ­¹ã·º¿ªÕ¹(Mossine, V, 2008; Sathisha, Jayaram,Nayaka & Dharmesh, 2007)¡£Ä¿Ç°£¬ÉÐȱ·¦Ò»Ì׹㠷ºÈϿɵġ¢¸ßͨÁ¿µÄGal-3IɸѡҪÁ죬ÄÜÔÚBMPFsÖм°ÆäËüÀàÐÍGal-3IÎÄ¿âÖÐɸѡ³ö»îÐÔ¸ü¸ß¡¢¶¾ÐÔ¸üСµÄƬ¶Î¡£Ñо¿BMPFsµÄ¿¹Ö×Áö¹¹Ð§¹Øϵ¡¢´úл¶¯Á¦Ñ§µÈÓÐÖúÓÚÍƶ¯É¸Ñ¡¼Æ»®µÄ½¨Á¢£¬ÓÐÀûÓÚ»ñµÃÐÔÄܸüÓÅÔ½µÄÏȵ¼·Ö×Ó¡£,

          BMPFs.ÉϵÄÆäËüÌDzлù,ÀýÈç°¢À­²®ÌÇ»á¶ÔÆä»îÐÔ±¬·¢Ó°Ïì¡£Gao(Gao,et al,2013)ÊӲ쵽°¢À­²®ÌǼȿÉÒÔÔö¼Ó¡¢Ò²¿ÉÒÔ¼õÉÙ°ëÈé¹Ñ¾ÛÌÇƬ¶ÎÓëGal3¼äµÄÏ໥×÷Óá£ÓеÄÄý¼¯ËØÆäÅä»ùµÄµ¹ÊýµÚ¶þ¸öÌDzлù»áÓ°ÏìÆäʶ±ðר-ÐÔ(Nakahara,&Raz,A.2008).¡£Ä¿Ç°ÉÐδÓÐÑо¿BMPFsÆäËûÄ©¶ËÌDzлù¶ÔÆäר-ÐÔÓ°ÏìµÄ±¨µÀ¡£ÓÉÓÚÌåÄÚÓÐÊ®¼¸ÖÖ°ëÈéÌÇÄý¼¯ËØ£¬Òò¶ø£¬¶ÔÅäÌåÄ©¶ËÅâ²Ð»ùµÄ½á¹¹Ñо¿ÊÇÐëÒªµÄ¡£

          Gal-3Óë¶àÖÖ¼²²¡ÓйØ£¬BMPFsÈçºÎÓ°ÏìGal-3Ïà¹ØµÄ¼²²¡£¬Ñо¿Àý×Óδ¼¸¡£Ò»¸öÓйصÄÀý×ÓÊÇ£¬MCP¶ÔСÊóʵÑéÐÔÉöËðÉËÓб£»¤×÷Óã¬Õâ¿ÉÄÜÓëMCPµ÷µÍ

      Gal-3µÄ±í´ïˮƽÓйØ£¬Í¬Ê±MCP²»Ó°ÏìGal-1 ºÍGal-9µÄ±í´ïˮƽ(Kolatsi-Joannou, Price, Winyard, & Long, 2011)¡£ÌåÄÚ±£´æÆäËü»îÐÔ¸÷ÒìµÄ°ëÈéÌÇÄý¼¯ËØ(ÖÁÉÙÓÐÊ®ÎåÖÖ),ËüÃǾùʶ±ð¾ßÓаëÈéÌÇδ¶ËµÄ·Ö×Ó£¬Òò¶ø²»¿ÉÅųýBMPFsÓëGal-3 Ö®ÍâµÄ°ëÈéÌÇÄý¼¯Ëر¬·¢Ï໥×÷ÓõĿÉÄÜÐÔ(Heusschen,Grifioen, & Thissen, 2013)¡£BMPFs ÆäÌåÄڵİеã³ýGal-3Í⣬ÊÇ·ñ»¹Äܹ»ÓëÆäËû¼Ò×åµÄ°ëÈéÌÇÄý¼¯ËØ(ÀýÈçASGP-R)¡¢Ï¸°ûÒò×Ó(Liu et al, 2001; Salman,Bergman, Djaleti, Orlin, & Bessler, 2008)¡¢ËÀÍöÊÜÌå(Chauhan et al, 2005)Ï໥×÷Óã¬Óдý½øÒ»²½Ñо¿¡£

          6.¹û½ºÔÚ¿¹°©¸øҩϵͳÖеÄÓ¦ÓÃ

          ¹û½ºÊÇÒ»ÖÖÐí¶à¹ú¼ÒÅú׼ʹÓõÄÒ©Î︨ÁÏ¡£ÓÉÓÚËü¾ßÓÐôÇ»ù¡¢ôÈ»ùµÈ¹¦Ð§»ùÍÅ£¬Ò×ÓÚÐÞÊΣ¬ÎÞ¶¾ÐÔ£¬Òò¶øÔÚ¸øҩϵͳÖÐÓ¦Óù㷺¡£Æ¾¾Ý¸øҩ;¾¶£¬¹û½º¸øҩϵͳ·ÖΪ賦µÀ(¾­¿Ú·þ)¸øÒ©ºÍ·Ç賦µÀ¸øÒ©¡£Î¸³¦µÀ¸øÒ©µÄÖØÒª·½·¨Êǽ᳦¸øҩϵͳ(colon-specific drug delivery system, CSDDS),½ÓÄÉ¿Ú·þ¸øÒ©£¬ÄÜÔö¼Ó²¡È˽ÓÊÜÖÎÁƵÄ˳ӦÐÔ(Dev, Bali, & Pathak, 2011; Wong, Colombo, & Sonvico,2011)¡£ÀûÓý᳦ÄÚϸ¾úÊͷŵÄø¿ÉÒÔ½µ½â¹û½ºµ¼ÖÂÊÍÒ©µÄÔ­ÀíÒÔ¼°¶Ô¹û½º½øÐÐÄý½º»¯¡¢¸Æ»¯¡¢¾ÛºÏ³Éй²¾ÛÎïµÄÒªÁì¿ÉÒÔÖƱ¸CSDDS, CSDDSÄÜÔöǿijЩҩÎïµÄÉúÎïÀûÓöÈ¡£Ò©´ú¶¯Á¦Ñ§ÊµÑéÖ¤Ã÷£¬»ùÓÚ¹û½ºµÄCSDDS¾ßÓÐÁ¼ºÃµÄ¾Ö²¿ÊÍÒ©ÄÜÁ¦£¬ÓÐÀûÓÚÖÎÁƽ᳦°©(He, Du, Cao, Xiang, & Fan, 2008)¡£·Ç賦µÀ¸øÒ©ÐèҪʹÓøÄÐԵĹû½º¡£ÀýÈ磬- -ÖÖÒÔõ£°·»¯¹û½ºÎªÔØÌåµÄDNAÔØÔËϵͳ£¬Ê¹ÓÃÁË´øÓÐÕýµãµçºÉµÄ¹û½º¸ÄÐÔ·Ö×Ó£¬Äܹ»Ê¹ÍâÔ´»ùÒòת»¯½øÈëHEK293ϸ°ûÄÚ(Katavet al.2008)¡£µÍõ¥¹û½º(·Ö×ÓÁ¿< 50 00Da)Ó밢ùËØéîºÏµÄ¸øҩϵͳ£¬¾­ÊóÄ£ÐÍÌåÄÚʵÑéÖ¤Ã÷£¬ÄÜÒÖÖÆÐþÉ«ËØÁöתÒÆ(Tang et al, 2010)¡£¹û½ºµÄRG-IƬ¶Î¸»º¬Ä©¶Ë°ëÈéÌÇ£¬¶ø¸ÎÔàÍâòµÄÒ»ÖÖ°ëÈéÌÇÄý¼¯ËØ- -ASGP-R »òÐíÄܹ»Ê¶±ðÕâÀàÌDzлù¡£Òò¶ø£¬ÀûÓùû½º»òÕßMCPÄÜ¿ª·¢Õë¶Ô¸Î°©µÄÆ÷¹Ù°ÐÏò¸øҩϵͳ(Yuetal,2014)¡£

          ±ðµÄ£¬¹û½º¿ÉÒÔÖ±½Ó¾­ÐÞÊÎÓ뿹Ö×ÁöÒ©Îï½øÐл¯Ñ§½»ÁªÉè¼Æǰҩϵͳ£¬»òÖƱ¸³ÉË®Äý½º¡¢Î¢ÇòµÈÖÖÖÖÐÎʽµÄ¿¹°©Ò©ÎﻺÊÍϵͳ(Puga, Lima, Mano, Concheiro,& Alvarez-Lorenzo, 2013; Takei, Sato, ljima, & Kawakami, 2010)£¬ÕâЩ¸øҩϵͳÓÐ

    ÀûÓÚ¼õÇữÁÆÒ©ÎïµÄ¶¾ÐÔ»ò¸ÄÉÆÆäÉúÎïÀûÓöÈ.ÖÎÁÆ°©Í´µÄ¹û½ºéîºÏ·Ó̪Äá¸øҩϵͳÒѾ­½øÈëÁÙ´²Ñо¿(NCT02050503)¡£

    7.½áÓï

          ±¾ÎĶÔDF-Pec¡¢BMPFs¼°¹û½º¸øҩϵͳÔÚ¿¹Ö×ÁöÖÎÁÆ·½ÃæµÄÓ¦ÓýøÐÐÁË×ܽᣬ²¢Öصã¶ÔBMPFsµÄ¿¹Ö×Áö»úÖƺ͹¹Ð§¹Øϵ½øÐÐÁËÏêϸÆÊÎö¡£ÌìÈ»¹û½º½á¹¹ÅӴ󡢿¹Ö×Áö¹û½º¹¦Ð§Ê³Æ·¹æ¸ñ·×Æ磬²»¹ý´ó²¿·Ö±¨¸æÖ§³ÖDF-PecÄÜ·ÀÖν᳦°©£¬Æä»úÖÆÉæ¼°ÒÖÖÆ·¢°©ºÍÃâÒßµ÷Àí¡£Ï¸ÖÂÀí½âDF-Pec µÄ¿¹Ö×Áö¹¹Ð§¹ØϵÓÐÖúÓÚ¸ïвúÆ·¹¦Ð§£¬ÒÔ»ñµÃ½á¹¹ºÍ¹¤ÒÕ¸ü- -Ö¡¢¿É¿ØµÄ²úÆ·£¬ÓÐÖúÓÚ»ñµÃЧ¹û¸ü¼ÑµÄ»ùÓÚ¹û½ºµÄ±£½¡Æ·(nutraceutical)(McCarty & Block, 2006)¡£×ÜÌå¶øÑÔ£¬½«¹û½º¼°Æä¸ÄÐÔÎ↑·¢Îª¿¹°©Ò©ÎïµÄÔØÒ©ÖÊÁÏËùÃæÁÙµÄÌôÕ½ÉÙÓÚ½«BMPFs¿ª·¢³ÉΪ¿¹Ö×ÁöÒ©ÎïµÄÀú³Ì¡£

          һЩ»ú¹¹¿ªÊ¼×ÅÊÖ½«BMPFs¿ª·¢³ÉÒ©Îµ«»¹±£´æÐí¶àÎÊÌâÓдý½â¾ö¡£ÀýÈ磬¹û½º½á¹¹ÈçºÎÊܼӹ¤Àú³ÌºÍ³¦µÀ¾úȺµÄÓ°Ïì;¼ÁÐͺ͹û½ºµÄÄý½º»¯ÈçºÎÓ°ÏìÆäÉúÎïÀûÓöÈ;½ÓÄÉÔõÑùµÄ±ê×¼ÓÅ»¯¸ÄÐÔÀú³Ì;ÈçºÎ¿ØÖÆÆä·Ö×ÓÁ¿ÂþÑÜ( Zhang, etal, 2010);ÈçºÎÍêÉÆÖÊÁ¿¿ØÖƼƻ®;ÔÚÌåÄÚÁíÓÐÄÄЩÒòËØÓ°ÏìBMPFsÓë°Ðµã¼äµÄÏ໥×÷ÓÃ;BMPFsÔÚ¿¹Ö×Áöʧ³²µòÍö·½ÃæÔÚ°ûÄÚÆð×÷ÓÃÕÕ¾ÉÔÚ°ûÍâÆð×÷ÓÃ;BMPFsÔÚÌåÄÚÊÇ·ñ»áÕûºÏ²¬ÀàÒ©Îï?ÈËÌåÄܹ»±¬·¢Ò»ÖÖÕë¶ÔÊóÀîÌǵĿ¹Ìå(Pazur, Erikson, Tay, & Alen, 1983)¡£Èç¹ûBMPFs±£´æÉÙÁ¿Ä©¶ËÊóÀîÌÇÌÇÜÕ£¬ºã¾ÃÖظ´Ê¹ÓÃBMPFsÊÇ·ñ»áÓÕµ¼ÌåÄÚ±¬·¢Çå³ýËüÃǵĿ¹Ìå?BMPFs¿ÉÒÔÖÎÁÆGal-3Ïà¹ØµÄÆäËû¼²²¡(KolatsiJoannou, 2011),¶ÔÕâЩ¼²²¡µÄÖÎÁÆ»á¶ÔÖ×ÁöÖÎÁƱ¬·¢Ê²Ã´Ó°Ïì?½øÒ»Ò»²½µÄÊÂÇéÄܹ»¸ÄÉÆBMPFsµÄ»îÐÔ»òÕßÀ©Õ¹ÆäÓ¦ÓÃÁìÓò¡£ÀýÈ磬ÊÇ·ñ¿ÉÒÔͨ¹ý½«BMPFs½øÒ»²½ÐÞÊλñµÃÉúÎïÀûÓöȻòÇ׺ÍÁ¦¸üºÃµÄƬ¶Î?ÓëÎüÊÕÔö½ø¼ÁÅäºÏ¿É·ñÔö¼ÓÆäÉúÎïÀûÓöÈ?ÄÜ·ñ½«BMPFséîºÏÓ«¹â·Ö×Ó±ê¼Ç»òÕßÁ¿×ӵ㣬³ÉΪGal-3¡¢Ñ­»·Ö×Áöϸ°û»òÕß΢תÒƵļì²âÊÔ¼Á¡¢Ê¾×Ù¼Á? BMPFsÖ±½ÓÕվɼä½ÓÓ°Ïìϸ°ûÒò×ӵĹ¦Ð§(Dennis, Lau, Demetriou, & Nabi, 2009) ?Õë¶ÔÈç´ËÖ®¶àµÄÎÊÌ⣬×÷ÕߵĽ¨ÒéÊÇÓ¦ÖصãÉîÈëÑо¿Gal-3µÄ¹¦Ð§Óë±í´ïÇé¿ö¡¢Æ÷¹ÙÂþÑÜ¡¢BMPFs µÄ¹¹Ð§¹Øϵ£¬»ñµÃ¸ü¶àµÄҩЧѧ¡¢Ò©´úѧÒÔ¼°ÁÙ´²Ñо¿Êý¾Ý¡£

    Acknowledgement

          This work was supported by the Guide Project of Science and TechnologyResearch of Henan Education Department (12B350006). Authors would like todeclare no conflicts of interest.

    Abbreviations

    AG-I, type I arabinogalactan; AG-II, type I arabinogalactan; ASGP-R,asialoglycoprotein receptor; BMPF, Bioavailable modified pectin fragment; CP, citruspectin; CRD, carbohydrate recognition domain; CSDDS, colon- specific drug deliverysystem; DF, dietary fiber; DF-Pec, dietary fiber pectin; DM, degree of methylation;ECM, extracellular matrix; Gal-3, galectin-3; Gal-3l, galectin-3 inhibitor; GALT,gut-associated lymphoid  tissue;  GS, substituted  galacturonans;  HG,homogalacturonan; HTCP, heat-treated citrus pectin; MCP, modified citrus pectin;PUFA, polyunsaturated fatty  acids; RG-I, rhamnogalacturonan-I; RG-II,rhamnogalacturonan-I; SCFA, short-chain fatty acids; XGA, xylogalacturonan.

    References.

          Attari, F., Sepehri, H., Delphi, L., & Goliaei, B. (2009). Apoptotic and necroticeffects of pectic acid on rat pituitary GH3/B6 tumor cells. Iranian Biomedical Journal,13(4):229-36.

          Az¨¦mar, M., Hildenbrand, B., Haering, B., Heim M.E. & Unger, c. (2007).Clinical benefit in patients with advanced solid tumors treated with Modified CitrusPectin: a prospective pilot study. Clinical Medicine: Oncology, 1:73. -80.

          Avivi-Green, c., Polak-Charcon, s.. Madar, Z., & Schwartz, B. (2000a).Apoptosis cascade proteins are regulated in vivo by high intracolonicbutyrate concentration: correlation with colon cancer  inhibition. OncologyResearch, 12(2): 83-95.

          Avivi-Green, c.. Polak-Charcon, S., Madar, Z, & Schwartz, B. (2000b). Dietary

     Application of Pectin in Cancer Therapy: a Review

          Wenbo Zhang". Han Zhang", Ping Xu*

          (a. School of Life Science and Technology, Xinxiang Medical University, XinxiangHenan 453003, PR China; b. School of Pharmacy, Xinxiang Medical University,

          Xinxiang Henan 453003, PR China)

          Key words: cancer therapy, galectin-3, modified citrus pectin, pectin



     



     



  • ÉÏһƪ£º Ç¿´óµÄÖ²ÎïÅä·½£ºÒ»ÖÖ¶Ô¿¹°©Ö¢µÄÐÂÐÍÎäÆ÷
    ÏÂһƪ£º¹û½ºµÄ¿¹Ö×Áö»îÐÔÑо¿½øÕ¹
  • ·µ»ØÐÂÎÅÁбí
 

    ÁªÏµ918²«ÌìÌÃ

  • µØµã£ºÕã½­Ê¡áéÖÝÊж«¸Û¾­¼Ã¿ª·¢Çø¶«¸Û4·2ºÅ
  • ÁªÏµµç»°£º0570£­8788056
  • ×ÉѯÈÈÏߣº400-7118-600
  • E-mail£ºzjgykp@163.com

Coptyright © 2018 zjgykp.com All Rights Reserved. °æȨËùÓÐ 918²«ÌìÌà  ¼¼ÊõÖ§³Ö£ºÕã½­Ö¥Â鿪ÃÅ  ÕãICP±¸19048970ºÅ-1|ºǫ́ÖÎÀí
ÍøÕ¾µØͼ
ÓÑÇéÁ´½Ó£ºÈËÉú¾ÍÊDz«  AG¾ÅÓλᠠÃ×ÀÖM6  918²©ÌìÌÃapp  ng28ÄϹ¬  ¿­·¢¹ÙÍøÈë¿Ú  qyÇòÓÑ»áÌåÓý  918²©ÌìÌà ¾ÅÖÝ¿áÓΠ 3377ÌåÓý  ÀûÀ´¹ú¼Êag  ÄϹ¬NG28  UG»·Çò¹ÙÍø  918²©ÌìÓéÀÖ  Ôƶ¥¼¯ÍŹÙÍø